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Drug capture efficacy using polystyrenesulfonate-coated chemofilter device 
Emilie Decavel-Bueff 
Abstract 
Endovascular chemotherapy is an effective treatment option for cancer, however, the 
therapeutic agents used in this procedure often travel to non-target tissues and cause severe 
toxicity. Side-effects of chemotherapy range from nausea to life-threatening conditions. A 
strategy to reduce exposure of healthy tissues and organs to the toxicity of chemotherapeutic 
agents, such as doxorubicin (DOX), is to remove these drugs from systemic circulation after they 
have passed through the tumor site. With this goal in mind, different types of ChemoFilter 
devices have shown promise in alleviating these detrimental side effects. When placed 
downstream from the targeted tumor during intra-arterial chemotherapy, excess therapeutic 
agents bind to the device, preventing them from entering systemic circulation. In this study, we 
evaluated the doxorubicin-binding efficacy of a 3D printed porous cylindrical ChemoFilter 
device coated with sulfonated pentablock copolymers. Closed-circuit flow models experiments 
integrating 11 devices (uncoated or coated) at two concentrations of DOX (0.01 mg/mL and 0.05 
mg/mL) were conducted. Samples collected from these flow models were used to treat H9c2 cell 
cultures, a rat embryonic cardiac cell line selected due to DOX cardiotoxicity. After a 24-hour 
treatment period, cell viability was calculated using the Trypan blue exclusion method. At 0.01 
mg/mL DOX and 0.05 mg/mL DOX, the 3D printed polystyrenesulfonate-coated absorbers 
effectively filtered and eliminated DOX toxicity, increasing the H9c2 cell viability by 12.97% 
and 23.11%, respectively. These results confirm the ChemoFilter’s ability to successfully absorb 
DOX in vitro, showing promise for its possible future use in clinical trials.  
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 1 
Introduction 
Since 1991, overall cancer prognosis and survival have increased due to substantial 
developments made in early diagnosis and treatment strategies, with death rates declining by 
27%1. However, according to the World Health Organization, cancer was still the second leading 
cause of death in 2018, killing roughly 9.6 million individuals globally2. Most notably, the 
number of cases of liver cancer have more than tripled in the last few decades in the US alone1. 
In fact, hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is the 
third most common cause of cancer-related mortality worldwide3. This is predominantly 
observed among men, and even more so among those who are less educated4. 
There are many treatment options available for HCC, including radiofrequency ablation, 
surgical resection, radiation therapy, and trans-arterial procedures5. Although liver 
transplantation is the most curative approach for HCC, recurrence rates remain high and less than 
20% of patients qualify for surgery5,6. Due to strict patient eligibility criteria and to the shortage 
of donors, transplantation is not a viable option for many patients7. Instead, the standard of care 
for inoperable intermediate-stage HCC is trans-arterial intervention, including trans-arterial 
chemoembolization (TACE) and intra-arterial chemotherapy (IAC)7. Both are fluoroscopy-
guided, minimally invasive procedures that use a catheter to deliver the chemotherapeutic agents 
directly to the tumor. While this targeted therapy approach does allow for more of the anti-cancer 
drug to reach the tumor, especially in comparison to conventional intra-venous chemotherapy, 
administered dose is still limited by severe side-effects. More than 50% of the injected drug 
travels past the tumor and enters circulation, affecting non-target tissues and causing systemic 
toxicity8.  
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In particular, doxorubicin (DOX), an anthracycline antibiotic widely used in the 
treatment of numerous solid organ cancers and commonly selected for HCC trans-arterial 
procedures, can be detrimental and potentially fatal to the patient9,10. Doxorubicin side effects 
include alopecia, neutropenia, mucositis, pericarditis, cardiomyopathy, left ventricular 
dysfunction, and congestive heart failure11,12. Despite this overwhelming limitation, studies have 
shown that increasing the dose of doxorubicin results in greater tumor suppression8,13. Thus, it is 
vital to find an effective method that would reduce the cardiotoxicity caused by doxorubicin 
while maintaining, or even improving, its clinical use as an anti-cancer drug. 
 A promising solution to reduce systemic toxicity is to incorporate a ChemoFilter device 
downstream of the tumor treatment site that would remove the excess drug before it enters 
general circulation (Figure 1). This could be implemented during an IAC procedure, as shown in 
Figure 2. An introducer sheath and 
guidewire would be used to 
temporarily place the filtration 
device in the hepatic veins draining 
the liver. After doxorubicin is 
infused into the hepatic artery, the 
drug would travel to the tumor, exit the liver, and be absorbed by the ChemoFilter before 
entering systemic circulation. Past studies have explored various binding methods that 
effectively filter doxorubicin and cisplatin from the bloodstream, such as sulfonated ion-
exchange resins, DNA, and magnets14–16.  
Figure 1. Concept for drug capture in blood vessel using two 3D 
printed polystyrenesulfonate-coated absorbers in parallel17. 
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For the purpose of this study, we assessed a 3D 
printed polystyrenesulfonate-coated absorber designed 
by Dr. Hee Jeung Oh. At physiological pH, 
doxorubicin’s amino functional group becomes 
protonated, giving the molecule an overall positive 
charge and a high affinity for anionic sulfonate groups 
(Figure 3). Electrostatic interactions between the 
positively charged nitrogen and negatively charged 
oxygen form an ionic bond and the sulfonate-coated 
absorber is able to bind to doxorubicin in blood. The 
device’s drug capturing efficiency has been 
demonstrated in vivo using swine models, with    
up to 64 ± 6% of doxorubicin successfully removed from circulation17.  
 
 
 
In our study, we evaluated in vitro the doxorubicin drug-binding efficacy of this 3D 
printed porous cylindrical filtration device coated with sulfonated pentablock copolymers. Our 
investigation aimed to confirm the filter’s ability to absorb doxorubicin, and therefore reduce 
systemic toxicity, as well as supplement data still currently being collected in in vivo studies. 
* 
Figure 3. Chemical structures of doxorubicin in its uncharged (A) and protonated (B) form, and 
the negatively charged sulfonate that coats the 3D printed absorber (C). When doxorubicin is in 
vivo (pH 7.4), the nitrogen marked by an asterisk (A) becomes positively charged (B) and binds to 
the anionic oxygen in the sulfonate group (C). 
 
Figure 2. Placement of filtration device 
(absorber) downstream of liver tumor site 
during an intra-arterial chemotherapy 
procedure17.  
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Due to the prevalence and importance of doxorubicin-induced cardiotoxicity, the H9c2 rat 
cardiac cell line was selected for our cultures. This cell line was originally derived from 
embryonic BDIX rat heart tissue by Kimes and Brandt in 1976, and is a well-established model 
of myocardium that has been historically used to evaluate the cardiotoxicity caused by anticancer 
drugs, including doxorubicin18–20.  
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Materials and Methods 
Although our present study of doxorubicin toxicity in cell cultures focuses on H9c2 cells, 
the immortal HeLa cell line was first used to become familiar with and to optimize cell culture 
protocols for the H9c2 cell line. Then, to assess the ChemoFilter’s ability to bind to doxorubicin 
and the residual toxicity to cardiac cells in vitro, samples taken from closed-circuit flow models 
with either uncoated or coated absorbers at different DOX concentrations were used to treat 
H9c2 cell cultures in toxicity experiments. After a 24-hour treatment period, percent cell 
viability was calculated to evaluate the filter’s drug-binding efficacy and DOX cardiotoxicity. 
Materials and Chemicals 
The porous cylinders of the absorbers were printed at Carbon, Inc (Redwood City, CA, 
USA). Dulbecco’s Modified Eagle’s Medium (DMEM), H9c2 cell line, 12-well cell culture 
plates, Steriflip vacuum filter, and bright line hemocytometer were purchased from Sigma-
Aldrich (St.Louis, MO, USA). Penicillin Streptomycin (10,000 units/mL), sterile Phosphate 
Buffered Saline (PBS) pH 7.4 (1X), and 0.05% Trypsin-EDTA 1X were procured from Gibco 
Life Technologies Corporation (Grand Island, NY, USA). Dimethyl Sulfoxide (DMSO) and 6-
well cell culture plates were purchased from Fisher Scientific (Hampton, NH, USA). Fetal 
Bovine Serum (FBS) was obtained from HyClone Laboratories (South Logan, UT, USA), DNase 
I from STEMCELL Technologies (Vancouver, BC, CA), 0.4% Trypan blue Solution with 0.85% 
NaCl from Lonza (Walkersville, MD, USA), CytoOne T-75 tissue culture flasks from USA 
Scientific (Ocala, FL, USA), and doxorubicin hydrochloride (2 mg/mL) from United States 
Pharmacopeia (New York, NY, USA). Serological pipets, micropipette tips, and conical tubes 
(50 mL and 15 mL) were obtained from Corning (Corning, NY, USA). NIS-Elements Advanced 
Research software was used to take images on the Nikon Eclipse TE2000-E inverted phase 
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contrast microscope, and the AmLite software was used to capture images on the Nikon Eclipse 
TS100 with the AMScope MU Series camera attachment. Images were processed and adjusted 
on ImageJ 2. 
Flow Model Experiments 
In order to simulate intra-arterial delivery of chemotherapy agents and their capture by a 
specialized ChemoFilter device, an in vitro closed-circuit flow model was developed by Patel 
and colleagues (Figure 4)21. This model used polyvinyl chloride tubing with a diameter similar to 
that of the human hepatic vein (1.2 cm) and a peristaltic pump to maintain a constant flow rate to 
match human hepatic blood flow (750 mL/min). Two different concentrations of doxorubicin 
were tested: 0.01 mg/mL and 0.05 mg/mL in 500 mL of 
PBS, which was heated to 37°C. These dosages are 
within the range of concentrations that have been used in 
clinical TACE procedures22. Flow models at each of the 
described doxorubicin concentrations were performed 
using 11 coated (experimental) or uncoated (control) 
filtration devices inserted within the tubing. For the 
uncoated filters, up to 2 mL samples were taken at time point zero. For the coated devices, 2 mL 
samples were collected after equilibrium had been reached in the system. This occurred at hour 2 
for the 0.01 mg/mL concentration and at hour 6 for the 0.05 mg/mL concentration. These 
samples represent the amount of systemic doxorubicin in circulation following chemotherapy 
treatment. All samples were then filter-sterilized and used to treat H9c2 cell cultures to assess 
toxicity. 
 
Figure 4. In vitro closed-circuit flow 
model21. 
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HeLa Cell Cultures  
The HeLa cell line is derived from human cervical epithelial carcinoma23. The HeLa cells 
were cultured in high glucose (4.5 g/L) DMEM supplemented with antibiotics (100 units/mL 
penicillin and 100 μg/mL streptomycin) and 10% FBS at 37°C in a humidified atmosphere οf 5% 
CO2. Every 2-3 days, cells reached 90% confluence and were treated with 0.05% trypsin/EDTA 
solution in order to detach the cells from the flask surface on which they adhered. The collected 
cells were then centrifuged (200×g for 5-10 min at 22°C). The cell pellets were resuspended in 
10 mL of fresh, complete media and subcultured into 75-cm2 flasks at a ratio of 1:2, with each 
flask containing 5 mL of cell suspension. 
Cells were seeded into 6-well tissue culture plates to explore optimal seeding conditions. 
Both the ideal ratio of cell suspension to media and the total volume of cell suspension per well 
were evaluated. Dilution of cell suspension in complete media consisted of 1:5, 1:2, 1:1, 2:1, and 
5:1 (3 mL total volume), and volumes tested were 3 mL, 2 mL, and 1.5 mL (1:1 dilution only). 
Each test volume was also treated with or without doxorubicin (0.05 mg/mL) for 24 hours 
immediately after plating. Images were acquired every two hours for eight hours, and a final 
image was captured at 24 hours. 
H9c2 (2-1) Cell Cultures  
The H9c2 cell line was grown in 75-cm2 tissue culture flasks in high glucose (4.5 g/L) 
DMEM containing 10% FBS and antibiotics (100 units/mL penicillin and 100 μg/mL 
streptomycin) and incubated in a humidified atmosphere of 5% CO2 at 37°C. Culture medium 
was replaced every 2-3 days, and the cells were subcultured at 70-80% confluence to maintain 
their proliferative, undifferentiated state. Upon reaching confluency, cells were rinsed twice with 
sterile PBS to remove residual medium, and they were then temporarily incubated in 0.05% 
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trypsin/EDTA solution. When 90% of the cells were dissociated, medium was added to inhibit 
trypsin activity. The resulting suspension of cells was centrifuged at 120×g (4°C) for 5 minutes 
and the cell pellet was resuspended in 5 mL of fresh medium. To ensure the correct seeding 
density of 1×104 cells/cm2 during passaging and plating, Trypan blue and a hemocytometer were 
used to calculate cell density. To reduce clumping caused by prolonged treatment with trypsin, 
cells of passage 8 were incubated in DNase I for 15 minutes at room temperature. For passages 
4, 7 through 12, and 15, an aliquot of cells was frozen in a freezing medium made of 10% 
DMSO and 90% FBS. This allowed for re-culturing of cells from earlier passages to repeat 
experiments, if needed. 
Toxicity Study Protocol  
H9c2 cells were seeded (~35,000 cells/mL) into 6-well plates with a total cell suspension 
volume of 2 mL per well, or into 12-well plates with a total cell suspension volume of 800 μL 
per well. For each toxicity experiment, cells were divided into nine treatment groups (n=3): a 
Negative Control (PBS only) and four different conditions for each initial concentration of 
doxorubicin (0.01 mg/mL and 0.05 mg/mL): 
1. Coated Filter — samples taken from the flow model integrating coated absorbers 
2. Uncoated Filter — samples taken from the flow model integrating uncoated absorbers 
3. 0.45 µM or 2.24 µM — stock solution of doxorubicin (2 mg/mL) diluted in PBS at the 
concentrations indicated above prior to treating cell cultures 
4. 18.31 µM or 89.75 µM — stock solution of doxorubicin used to acquire final 
concentration (0.01 mg/mL or 0.05 mg/mL) within each well after treatment 
All cell culture plates were incubated in a humidified atmosphere of 5% CO2 at 37°C for 24 
hours to facilitate adhesion. After attachment, 50 μL (for the 6-well plates) or 20 μL (for the 12-
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well plates) of the appropriate treatment was introduced to each well and left for an additional 
24-hour period. These incubation and treatment periods of 24 hours are commonly used in 
cytotoxicity studies in this cell line24–28. 
Every 2-6 hours during the treatment period, cells were observed through a Nikon Eclipse 
TE2000-E inverted phase contrast microscope to evaluate their morphological changes over 
time, obtain preliminary cell counts, and capture images. To ensure that the same center location 
of each well was consistently used for cell counting, reference marks were drawn on a paper 
placed under the cell culture plates. Additional images were taken 24 and 48 hours after 
incubation on the Nikon Eclipse TS100 using the MU Series camera attachment. Trypan blue 
was used to obtain accurate counts of live and dead cells at the end of the 24-hour treatment 
period.  
Cell Counting  
H9c2 cell viability was determined using the Trypan blue exclusion method. This dye 
penetrates dead cells through damaged membranes and stains them blue, while live cells remain 
Figure 5. One of the nine squares within the 3×3 grid of the hemocytometer after 24-hour treatment with (A) 
89.75 µM of doxorubicin and with (B) PBS (Negative Control). White arrows point to live cells while red arrows 
point to dead cells. Exclusion lines are in red. 
B. A. 
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colorless (Figure 5). Unadhered dead cells in the medium were included in the cell count. After 
the removal of the medium into a 15 mL centrifuge tube, adherent viable cells were rinsed twice 
with PBS before trypsinization. The cell pellet was then resuspended in 2 mL (for 6 well-plates) 
or 200 μL (for 12 well-plates) of complete medium, and a 50 μL aliquot was removed and 
diluted with 50 μL of 0.4% Trypan blue solution. 10 μL of that solution was pipetted to the 
hemocytometer and the 3×3 grid was visualized under a Nikon Eclipse TS100 with a 10x 
objective. The number of live and dead cells within all nine squares was counted and those 
touching the right or bottom boundaries were excluded. The following calculations were 
performed:  
 
Statistical Analysis  
Results from 2 independent experiments with triplicates are presented as mean ± standard 
error of the mean (SEM). Statistical analysis was performed using RStudio. Data was analyzed 
using one-way analysis of variance (ANOVA) followed by Tukey post hoc test. Statistical 
differences were considered significant when p < 0.05.  
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Results 
HeLa Cell Cytotoxicity 
For all volumes of cell 
suspension, HeLa cells never 
adhered at any time points and all 
cells were dead and floating in the 
solution when treated with 0.05 
mg/mL of doxorubicin (Figure 6). 
Density of adherent cells increased 
with increasing volume when cells 
were not treated with doxorubicin 
for 24 hours, with cell density below 
optimal in 1.5 mL and cells almost 
at 100% confluency in 3 mL of cell 
suspension. Similar cell structures 
and clumping patterns were Figure 6. Plating of HeLa cells at different volumes (3 mL, 2 mL, 
and 1.5 mL) and treated with (+) or without (-) 0.05 mg/mL DOX. 
Images taken at time points 0, 8, and 24 hr after the start of 
treatment. 
Figure 7. Plating of HeLa cells at 2 mL and treated with (+) or without (-) 0.05 mg/mL DOX. Images taken at 
time points 0, 2, 4, 6, 8, and 24 hours and at the same location within the wells. 
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identified in the images taken over time, confirming that the same area in the center of the wells 
was captured (Figure 7).  
H9c2 Cell Viability at 0.01 mg/mL DOX 
After incubating for 24 hours, H9c2 cells were adhered to the surface of the wells (Figure 
8). All adhered cells at this time point were flat and spindle-shaped, with a few rounded, brighter 
cells that were only partially adhered. Such cells were fully attached to the surface within three 
Figure 8. Doxorubicin-induced morphological alterations in H9c2 cells with 20x objective under the Nikon 
Eclipse TE2000-E inverted microscope. Initial DOX concentration for the flow model samples (Coated Filter 
and Uncoated Filter) was 0.01 mg/mL DOX. Images taken at the same location within the wells right before 
treatment (24 hr), and 6, 18, and 24 hours after treatment. Arrows of similar colors point to identical structures 
observed over time.  
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hours. As time progressed, cell density increased in most treatment conditions, except for 18.31 
µM DOX. This trend was more pronounced in the Negative Control, the Coated Filter, and the 
Uncoated Filter conditions. With higher densities, cells began to organize themselves into more 
orderly arrays, which was most 
evident in the Coated Filter at 
48 hr. Reduction in cell size 
and number was clearer when 
treated with 18.31 µM DOX. 
Within the cells, deterioration 
started at the periphery and 
progressed inwards. Compared 
to the Negative Control, the 
nuclear size in 18.31 µM DOX 
increased slightly. 
Additionally, more partially 
adhered cells were visible in 
18.31 µM DOX at time 48 hr 
than at any other time point or 
for any other treatment 
condition. Such cells are more 
likely to be detaching than 
adhering.  
Figure 9. Effects of doxorubicin-induced cytotoxicity in H9c2 cell density. 
Images were taken pre-treatment (24 hours after plating) and post-treatment 
(48 hours after plating) under the Nikon Eclipse TS100 microscope with 
10x objective. Flow model DOX concentration for Coated Filter was 0.01 
mg/mL. 
 
 14 
Similar low cell densities, with cells randomly orienting themselves with respect to each 
other, were achieved for each condition before 0.01 mg/mL DOX treatments were introduced to 
the wells (Figure 9). After the 24-hour treatment period, the density of live cells in the Negative 
Control and Coated Filter conditions was comparable. While there were more unadhered dead 
cells at 0.45 µM DOX compared to the Coated Filter, the most obvious difference between those 
two conditions was a clear reduction in adhered live cells. These differences were even more 
pronounced in 18.31 µM DOX, which exhibited an abundance of floating cells and very few 
cells adhered to the well surface. 
For the treatment concentration of 0.01 mg/mL, H9c2 cell survival was significantly 
reduced when treated with 18.31 µM DOX, 0.45 µM DOX, and Uncoated Filter for 24 hours 
(Figure 10). Compared to Negative Control, cell viability decreased by 34.23% in 18.31 µM 
DOX and 12.53% in the Uncoated Filter. No statistical significance was found between 0.45 µM 
Figure 10. H9c2 cell cytotoxicity under the four conditions at 0.01 mg/mL of doxorubicin after 24 hours 
of treatment. Data presented as the mean percentage of cell viability relative to the Negative Control (*p 
< 0.05, **p < 0.0005, ***p < 0.0001 vs. Negative Control; +++p < 0.0001 vs. 18.31 µM DOX; &p < 0.05 vs. 
0.45 µM DOX; $$$p < 0.0001 vs. Uncoated Filter).  
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DOX and Uncoated Filter, or between the Negative Control and Coated Filter. However, cell 
viability did significantly increase by 12.97% from the Uncoated to Coated Filter. 
H9c2 Cell Viability at 0.05 mg/mL DOX 
As observed in the 0.01 mg/mL DOX treatments, almost all cells were fully adhered to 
the surface of the wells after 24 hours of incubation (Figure 11). Most adhered cells were flat and 
spindle-shaped, and only two rounded, partially adhered cells were visible. As time progressed, 
Figure 11. Doxorubicin-induced morphological alterations in H9c2 cells with 20x objective under the Nikon 
Eclipse TE2000-E inverted microscope. Initial DOX concentration for the flow model samples (Coated Filter 
and Uncoated Filter) was 0.05 mg/mL DOX. Images taken at the same location within the wells right before 
treatment (24 hr), and 6, 18, and 24 hours after treatment. Arrows of similar colors point to identical structures 
observed over time.  
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cell density increased in the Negative Control and the Coated Filter, while density decreased in 
the other treatment conditions. Notably, at the end of the treatment period, cells treated with 2.24 
µM DOX and Uncoated Filter had the same number of adherent cells. Similar trends in 
deterioration of cell structure and number observed at 0.01 mg/mL DOX were seen here at 0.05 
mg/mL DOX, with the addition 
of cytoplasmic vacuolization 
that started to develop as early 
as 3 hours after treatment. At 48 
hr 89.75 µM DOX, only one 
adhered, spindle-shaped cell 
was detected and many floating 
cells were out of focus. There 
were more cellular debris in 
89.75 µM DOX, at 21 hr and 48 
hr.  
Again, essentially 
identical cell densities were 
achieved for each condition 
before 0.05 mg/mL DOX 
treatments began (Figure 12). 
After cells were treated for 24 
hours, the density of live cells 
between the Negative Control 
Figure 12. Effects of doxorubicin-induced cytotoxicity in H9c2 cell 
density. Images were taken pre-treatment (24 hours after plating) and post-
treatment (48 hours after plating) under the Nikon Eclipse TS100 
microscope with 10x objective. Flow model DOX concentration for 
Coated Filter was 0.05 mg/mL.  
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and Coated Filter was comparable. In 2.24 µM DOX, post treatment, more unadhered dead cells 
were observed with fewer viable cells adhered to the surface of the well. At 89.75 µM DOX, 
only a handful of adhered cells could be seen under the dense population of floating dead cells.  
H9c2 cell survival was significantly reduced when treated with 89.75 µM DOX, 2.24 µM 
DOX and Uncoated Filter at 0.05 mg/mL for 24 hours (Figure 13). At that concentration, 
compared to the Negative Control, cell viability decreased by 69.95% in 89.75 µM DOX, and by 
24.45% in Uncoated Filter. No statistical significance was found between 2.24 µM DOX and 
Uncoated Filter, or between the Negative Control and Coated Filter. However, cell viability did 
significantly increase by 23.11% from the Uncoated to Coated Filter. 
  
Figure 13. H9c2 cell cytotoxicity under the four conditions at 0.05 mg/mL of doxorubicin after 24 hours of 
treatment. Data presented as the mean percentage of cell viability relative to the Negative Control (***p < 0.0001 
vs. Negative Control; +++p < 0.0001 vs. 89.75 µM DOX; &&&p < 0.0001 vs. 2.24 µM DOX; ###p < 0.0001 vs. 
Uncoated Filter). 
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Discussion and Conclusion 
The aim of this study was to assess the doxorubicin drug-binding efficiency of the 3D 
printed polystyrenesulfonate-coated absorber. This was done by conducting flow model 
experiments integrating the device (uncoated or coated) at the two concentrations of doxorubicin 
(0.01 mg/mL and 0.05 mg/mL). H9c2 cell cultures were treated with the supernatants collected 
from the described flow models, and the resulting cell viability was calculated after 24 hours of 
treatment. The coated device successfully absorbed significantly more doxorubicin than the 
uncoated filters at both concentrations, resulting in H9c2 cell viability similar to the Negative 
Control. These results confirmed the efficacy of the absorber in vitro and will help pave the way 
to implement the devices in clinical human studies. 
HeLa Cell Cytotoxicity 
The HeLa cell line has been used to study the effects of toxic agents, such as nitrogen 
doped carbon quantum dots, nickel nanotubes, and the proteasome inhibitor epoxomicin29-31. Our 
preliminary study conducted on HeLa cells aided in establishing and optimizing an effective 
experimental protocol for the H9c2 cell line. The lack of adherent cells at any time points after 
doxorubicin treatment revealed that an incubation period for the H9c2 cells would be necessary 
(Figure 6). This would give viable cells adequate time to adhere to the surface prior to treatment 
so that the cellular damage caused by the chemotherapeutic agent could be evaluated. 
Additionally, allowing the healthy cells to adjust and grow into their normal morphology is a 
more clinically relevant representation of in vivo conditions. Based on the images acquired from 
the HeLa cell line experiments, a dilution factor of 2 and a plating volume of 2 mL achieved the 
optimal seeding density to best visualize individual cells over time (Figure 6). When HeLa cells 
were incubated without doxorubicin, they remained adhered to the well surface and continued to 
 19 
spread by webbing: extending lamellipodia and filopodia with protoplasm filling the space in 
between (Figure 7)32. In sharp contrast, cells treated with the drug were exclusively round in 
shape and free-floating. Similar results were expected for the application on H9c2 cells. Due to 
the prevalence of cardiotoxicity induced by doxorubicin, we used this cell line of rat 
cardiomyoblasts for the remainder of our study. 
H9c2 Cell Cardiotoxicity  
H9c2 cardiomyoblast cells grown in culture dishes can be categorized into three 
subgroups: adherent, sub-adherent, and non-adherent. Typically, if cells have not started to 
adhere to the surface of the dishes within 24 hours of plating, then they were considered dead. 
Examples of these rounded, floating, and brighter cells can be seen in Figures 9 and 12 (Pre-
treatment), which show images taken after the 24-hour incubation period. On the other hand, 
both adhered and partially adhered cells are considered live and can come in a variety of shapes: 
spherical, polygonal, and, more commonly, flat spindle-to stellate33. Most cardiomyoblasts are 
mononucleated and contain one to four nucleoli within their nuclei, a morphology which was 
generally observed within our H9c2 cell cultures18.  
When H9c2 cells were incubated in doxorubicin, major structural changes occurred, 
including nuclear swelling, decrease in cell size, peripheral degeneration, membrane blebbing, 
and cell rounding (Figures 8 and 11). These morphological changes were more evident at higher 
DOX molar concentrations, with cytoplasmic vacuolization appearing at 89.75 µM DOX, 
demonstrating the relationship between DOX dose and cytotoxicity. As cells were exposed to the 
drug over time, flat cells began to detach from the well surface, remaining only partially adhered 
through long cytoplasmic filopodia, until they were completely dissociated33. These observable 
changes are helpful in understanding how the chronic exposure to doxorubicin chemotherapy 
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affects cardiac cells. When looking at our images, it is important to note that the inconsistencies 
in cell density in response to treatment, such as the Uncoated Filter at 0.01 mg/mL DOX, are a 
consequence of the capture of a small area within the entire well using a 20x objective. Images 
taken using the 10x objective are more representative of how the population of cells were 
responding to DOX treatment. Within this larger field of view, we can clearly see that 89.75 µM 
DOX and 2.24 µM DOX were more fatal to H9c2 cells than the corresponding treatments at 0.01 
mg/mL DOX (Figures 9 and 12). Given that there was no significant change in cell viability 
between the lower molar concentrations (0.45 µM and 2.24 µM DOX) and the corresponding 
Uncoated Filter, we are able to interpret the images similarly. For each DOX concentration in the 
flow models, the density of adherent cells in the Coated Filter and Negative Control were 
identical, which is also supported by the non-significant difference in the calculated cell 
viabilities for those treatments (Figures 10 and 13). The stark qualitative and numerical 
differences between Coated Filter and 0.45 µM or 2.24 µM DOX (also interpretable as Uncoated 
Filter) is reflective of the filter’s drug-binding capabilities at both 0.01 mg/mL and 0.05 mg/mL 
DOX. This indicates that at each of the respective DOX concentrations, the 3D printed 
polystyrenesulfonate coated absorber is able to effectively eliminate DOX toxicity, allowing the 
cardiac myoblasts to thrive similarly to the Negative Control. 
Limitations and Future Directions 
In order to assess the cardiac cytotoxicity of doxorubicin, cell viability was calculated by 
utilizing the Trypan blue exclusion method. While live cells have intact cell membranes and 
exclude this dye, dead cells become stained blue due to their ruptured membranes34. Since the 
early 1900s, Trypan blue has been the gold standard for counting the number of live and dead 
cells in a variety of applications35,36. Such uses have included counting white blood cells in urine 
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sediments of dogs in veterinary pathological studies, and measuring the cytotoxicity of dibutyl 
phthalate on macrophages in immunopharmacology experiments37,38. Despite its extensive use in 
laboratory procedures, it has some limitations. Research has shown that Trypan blue is toxic to 
mammalian cells, often causing major and irreversible morphological changes within minutes of 
exposure. Tsaousis and colleagues found that the calculated cell viability of human trabecular 
meshwork cells decreased by 11% after only 5 minutes of exposure, and by 16% after 15 
minutes39. To mitigate this issue, we counted H9c2 cells within 3 to 5 minutes of diluting the cell 
suspension with Trypan blue. Furthermore, while it is effective in staining the cytoplasm of dead 
cells, Trypan blue is not able to distinguish accurately between viable cells and cells that are 
alive, but dying40. A possible solution for this would be to assess cell viability by other means, 
such as the commonly used MTT colorimetric assay34. Instead of relying on the integrity of the 
cell membrane, this assay measures cell proliferation, or the quantity of cells that are actively 
dividing, and therefore is able to quantify the proportion of healthy cells in a population. 
Specifically, this assay measures the mitochondrial metabolic rate of active cells41. In the 
presence of these cells and through the action of dehydrogenase enzymes, the yellow tetrazolium 
salt 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is reduced to purple 
formazan crystals, which can then be dissolved and the optical density measured with a 
spectrophotometer 42. 
The flow model samples used in this study to treat H9c2 cells is another area that could 
be improved, specifically the final concentration of DOX in the cell cultures. The initial design 
of this study was to evaluate the drug-binding capabilities of the ChemoFilter device at two 
specific concentrations of doxorubicin (0.01 mg/mL and 0.05 mg/mL), concentrations selected 
due to their clinical use in chemotherapy, and then to treat the cell cultures with samples 
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acquired from the flow models43. However, since only a small aliquot of these samples (20 µL or 
50 µL) was transferred to the wells (initially containing 800 µL or 2 mL of cell suspension), it 
was concluded that all flow model and samples of DOX stock solution with PBS were diluted by 
a factor of 40. In fact, only two treatments had a final concentration of 0.01 mg/mL or 0.05 
mg/mL of doxorubicin within the wells: 18.31 µM and 89.75 µM DOX, respectively. On the 
other hand, the final molarity of doxorubicin for the samples that were diluted in PBS to acquire 
a concentration of 0.01 mg/mL or 0.05 mg/mL DOX prior to treating cell cultures was 0.45 µM 
and 2.24 µM DOX. Although the more diluted molar concentrations of doxorubicin have been 
used in similar H9c2 cardiotoxicity experiments, future studies could use DMEM as the solution 
in the flow models, instead of PBS44,45. Collected flow model samples could replace the medium 
in the H9c2 cell cultures, in which the final concentration would then reflect the true DOX 
concentration in the flow models.  
A significant benefit of temporarily deploying a highly efficient absorber in patients 
during intra-arterial chemotherapy is the ability to increase the therapeutic dosage in order to 
maximize tumor suppression, resulting in better patient outcome and minimizing severe side 
effects. To that effect, future investigations could explore the upper limits of this absorber’s 
capacity to filter doxorubicin. Determining at what concentration of doxorubicin the ChemoFilter 
would be able to successfully absorb enough of the drug and still result in a high percentage of 
cell viability in H9c2 cell cultures would provide valuable information in the future clinical use 
of these filtration devices.  
In conclusion, the 3D printed porous cylindrical filtration device coated with sulfonated 
pentablock copolymers demonstrated successful binding and absorption of doxorubicin from 
circulation within a closed-circuit flow model. At 0.05 mg/mL and 0.01 mg/mL of DOX, the 
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absorber increased the H9c2 cell viability by 23.11% and 12.97%, respectively. With the results 
acquired in this in vitro study supporting the data currently being collected in vivo, the future 
clinical implications remain quite promising. Implementation of this ChemoFilter device would 
ultimately enhance the effectiveness of a standard intra-arterial chemotherapy procedure by 
significantly reducing systemic toxicity and improving patient prognosis. Application of these 
absorbers could be extended to treat other solid organ tumors in addition to hepatocellular 
carcinoma. Similar devices could also be adapted to selectively absorb other chemotherapeutics, 
such as cisplatin, carboplatin, and epirubicin, or to potentially filter antibiotics and other drugs.   
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